Biosimilar sourcing isnt a procurement problemits a patent strategy problem.
If youre planning a switch from an originator to a biosimilar, the hardest part usually isnt identifying candidates. Its timing the switch so you capture volume and margin bef…

Pharma has a new way to sell the same storyjust with a different price tag.
In a world where patients are increasingly asked to wait for innovation, drugmakers are finding another lever: repurposed medicines. The molecules may be old. The indication ma…

Pharma recruiting is broken in a very specific way: most teams still treat best scientists like a vibe instead of a measurable signal.
If youve ever watched a search committee chase the same handful of CV buzzwordspatent experience, publication record,…

Old Drugs. New Prices. The Pharma Playbook Is Getting Sharper.
Theres a quiet shift happening across healthcareone that rarely makes headlines, but shows up fast in pharmacy benefit managers, formularies, and patient out-of-pocket costs.
A growing numb…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russias third wheel rule is supposed to be a footnote in the global drug supply chain. In practice, its a signal flareone that can tell you where Russia is headed next in APIs, full-cycle manufacturing, and the next wave of patent battles.
Heres the ag…

Europes patent system is supposed to do two things at once: reward innovation and keep markets competitive. But a growing body of evidence suggests its doing something elsedelaying final decisions long enough for brand incumbents to keep generics waiti…

Pharma patent litigation used to be a $50M inevitability.
Now, it’s increasingly a $5M decision—if you treat it like a portfolio problem, not a courtroom event.
That’s the core message behind a new playbook from DrugPatentWatch: cutting the cost of pat…

PBMs and rebates aren’t “background noise” anymore—they’re the business model.
If you’re a pharma executive, payer strategy isn’t a side project. It’s the battlefield. And the rules of engagement are changing faster than most organizations can update t…

Mark Cuban’s Cost-Plus Pricing Isn’t Just a Pricing Story—It’s a Patent-Playbook Story
The most important thing to understand about Mark Cuban’s cost-plus pricing push isn’t that it’s “cheaper.” It’s that it’s changing the incentives that have governed…